Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.

You may also be interested in...



Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug

Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings

MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug

Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation

Table

View full table

Related Content

Scrip
Scrip
Scrip
Tags:
Latest Headlines

China VBP, Localization And Other Strategies - How Far And Which Way?

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

See All
UsernamePublicRestriction

Register

SC068343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By